Victoria Forster

1 week ago | forbes.com | Victoria Forster

For the first time in 30 years, researchers have discovered a promising new antibiotic treatment for gonorrhoea, a potentially important milestone in the fight against growing antibiotic resistance. Gonorrhoea is one of several sexually transmitted infections which is fast-gaining resistance to existing antibiotic treatments, making it hard to effectively treat patients with drug-resistant strains of Neisseria gonorrhoeae, the bacteria responsible for the infection.

1 week ago | cancertherapyadvisor.com | Victoria Forster

Niraparib maintenance has a tolerable safety profile in patients with ovarian cancer, with hematologic toxicities being “the primary concern,” according to researchers. They evaluated the safety of niraparib in a meta-analysis and reported their results in the European Journal of Obstetrics & Gynecology and Reproductive Biology. The meta-analysis included 8 studies — 4 phase 3 randomized controlled trials (RCTs) and 4 observational studies — published between 2016 and 2024.

2 weeks ago | cancertherapyadvisor.com | Victoria Forster

New research suggests that most top-selling cancer drugs in the United States provide “high added therapeutic benefits.” However, researchers also found that cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022, and these drugs cost more per beneficiary than the drugs that confer high therapeutic benefits. Researchers reported these findings in JAMA Network Open.

2 weeks ago | forbes.com | Victoria Forster

A woman in the U.K. has become the first in the country to give birth after receiving a womb transplant from her sister. Grace Davidson, 36 gave birth on February 27th to a healthy baby girl via caesarean section at hospital in the U.K. At 19, Davidson was diagnosed with a rare condition called Mayer-Rokitansky-Küster-Hauser syndrome, meaning her womb was either missing or not developed properly.

4 weeks ago | cancertherapyadvisor.com | Victoria Forster

Many patients with metastatic clear cell renal cell carcinoma (ccRCC) are not receiving immune checkpoint inhibitors (ICIs) as first-line therapy, according to a study published in JAMA Network Open. The study included 8534 patients who were diagnosed with metastatic ccRCC between January 1, 2011, and January 20, 2023. All patients received first-line therapy, 48.4% received second-line therapy, and 23.7% received third-line therapy.